Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole.

Lemke MR, Brecht HM, Koester J, Kraus PH, Reichmann H.

J Neuropsychiatry Clin Neurosci. 2005 Spring;17(2):214-20.

PMID:
15939976
2.

Pramipexole. A review of its use in the management of early and advanced Parkinson's disease.

Dooley M, Markham A.

Drugs Aging. 1998 Jun;12(6):495-514. Review.

PMID:
9638397
3.

Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease.

Bennett JP Jr, Piercey MF.

J Neurol Sci. 1999 Feb 1;163(1):25-31. Review.

PMID:
10223406
4.

Pramipexole versus bromocriptine for levodopa-induced complications in Parkinson's disease.

Clarke C E, Speller J M, Clarke J A.

Cochrane Database Syst Rev. 2000;(3):CD002259. Review.

PMID:
10908539
5.

Pramipexole in the treatment of Parkinson's disease: new developments.

Möller JC, Oertel WH.

Expert Rev Neurother. 2005 Sep;5(5):581-6. Review.

PMID:
16162081
6.

Depressive symptoms in Parkinson's disease.

Lemke MR.

Eur J Neurol. 2008 Apr;15 Suppl 1:21-5. doi: 10.1111/j.1468-1331.2008.02058.x. Review.

PMID:
18353133
7.

Role of pramipexole in the management of Parkinson's disease.

Antonini A, Barone P, Ceravolo R, Fabbrini G, Tinazzi M, Abbruzzese G.

CNS Drugs. 2010 Oct;24(10):829-41. doi: 10.2165/11585090-000000000-00000. Review.

PMID:
20839895
8.

Pramipexole for levodopa-induced complications in Parkinson's disease.

Clarke C E, Speller J M, Clarke J A.

Cochrane Database Syst Rev. 2000;(3):CD002261. Review.

PMID:
10908540
9.

[Pharmacological profiles and clinical effects of antiparkinsonian agent, pramipexole].

Kohno Y, Takeuchi S.

Nihon Yakurigaku Zasshi. 2004 Jun;123(6):429-40. Review. Japanese.

PMID:
15170083
10.

Treatment of depressive symptoms in Parkinson's disease.

Barone P.

Eur J Neurol. 2011 Mar;18 Suppl 1:11-5. doi: 10.1111/j.1468-1331.2010.03325.x. Review.

PMID:
21255198
11.

Pramipexole extended release: in Parkinson's disease.

Chwieduk CM, Curran MP.

CNS Drugs. 2010 Apr;24(4):327-36. doi: 10.2165/11204570-000000000-00000. Review.

PMID:
20297857
12.

Clinical pharmacology of dopamine agonists in Parkinson's disease.

Lange KW.

Drugs Aging. 1998 Nov;13(5):381-9. Review.

PMID:
9829165
13.

Dopamine agonists in Parkinson's disease.

Yamamoto M, Schapira AH.

Expert Rev Neurother. 2008 Apr;8(4):671-7. doi: 10.1586/14737175.8.4.671. Review.

PMID:
18416667
14.

Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison.

Inzelberg R, Schechtman E, Nisipeanu P.

Drugs Aging. 2003;20(11):847-55. Review.

PMID:
12964891
15.

Ropinirole and pramipexole, the new agonists.

Hobson DE, Pourcher E, Martin WR.

Can J Neurol Sci. 1999 Aug;26 Suppl 2:S27-33. Review.

PMID:
10451757
16.

[Pramipexole and Parkinson's disease, an update].

Martínez-Corral M, Kulisevsky J.

Rev Neurol. 2008 Jan 1-15;46(1):49-52. Review. Spanish.

17.
18.

[Parkinson's disease].

Miyoshi K.

Nihon Rinsho. 2001 Aug;59(8):1570-3. Review. Japanese.

PMID:
11519161
19.
20.

Second generation of dopamine agonists: pros and cons.

Rabey JM.

J Neural Transm Suppl. 1995;45:213-24. Review.

PMID:
8748628
Items per page

Supplemental Content

Write to the Help Desk